Harmatys et al. designed 64Cu-LC-Pyro, a low molecular weight PSMA-targeted agent with long plasma circulation time and high tumor-to-background ratio (10:1) for PET/CT, NIRF imaging and NIR-PIT at the same time 112. This evidence concerns the gene FOLH1 and neoplasm.